KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Receivables - Other (2016 - 2024)

Historic Receivables - Other for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Q4 2024 value amounting to $2.1 million.

  • CRISPR Therapeutics AG's Receivables - Other fell 6769.23% to $2.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.1 million, marking a year-over-year decrease of 6769.23%. This contributed to the annual value of $2.1 million for FY2024, which is 6769.23% down from last year.
  • As of Q4 2024, CRISPR Therapeutics AG's Receivables - Other stood at $2.1 million, which was down 6769.23% from $6.5 million recorded in Q4 2023.
  • In the past 5 years, CRISPR Therapeutics AG's Receivables - Other ranged from a high of $25.0 million in Q1 2020 and a low of $2.1 million during Q4 2024
  • Moreover, its 5-year median value for Receivables - Other was $11.0 million (2020), whereas its average is $14.2 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first surged by 6400256.41% in 2020, then crashed by 6769.23% in 2024.
  • CRISPR Therapeutics AG's Receivables - Other (Quarter) stood at $10.7 million in 2020, then fell by 21.5% to $8.4 million in 2021, then surged by 33.33% to $11.2 million in 2022, then crashed by 41.96% to $6.5 million in 2023, then crashed by 67.69% to $2.1 million in 2024.
  • Its last three reported values are $2.1 million in Q4 2024, $6.5 million for Q4 2023, and $11.2 million during Q4 2022.